Recordati SpAMIL:REC +0.39%96 5-Year Yield-on-Cost % is 3.30 as of Jul. 09, 2026, which is 10% above its 10-year median of 3.01. GuruFocus rates MIL:REC with a GF Score™ of 96/100 and a GF Value™ of €60.80 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 516 Drug Manufacturers companies, Recordati SpA ranks better than 59.88% on this metric.
Recordati SpA's yield on cost for the quarter that ended in Mar. 2026 was 3.30.
The historical rank and industry rank for Recordati SpA's 5-Year Yield-on-Cost % or its related term are showing as below:
MIL:REC'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.17 Med: 3.01 Max: 3.94
Current: 3.3
During the past 13 years, Recordati SpA's highest Yield on Cost was 3.94. The lowest was 2.17. And the median was 3.01.
MIL:REC's 5-Year Yield-on-Cost % is ranked better than 59.88% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.255
vs MIL:REC: 3.30
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Recordati SpA 5-Year Yield-on-Cost % Related Terms
MIL:REC vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Recordati SpA's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Recordati SpA is calculated as
Recordati SpA (MIL:REC) has a 5-Year Yield-on-Cost % of 3.30 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Recordati SpA and its competitors. This is 10% above median its historical median of 3.01. Over the past decade, Recordati SpA's 5-Year Yield-on-Cost % has ranged from 2.17 to 3.94. According to the industry distribution chart, Recordati SpA ranks #207 out of 516 companies in the Drug Manufacturers industry, placing it in the top 40.1%.
Is Recordati SpA's 5-Year Yield-on-Cost % too high?
Recordati SpA's current 5-Year Yield-on-Cost % of 3.30 is 10% above median its 10-year median of 3.01. Over the past 10 years, this metric has ranged from a low of 2.17 to a high of 3.94. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.26. Recordati SpA's value of 3.30 is 46.3% above this industry median. Based on the distribution chart, Recordati SpA ranks #207 out of 516 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Recordati SpA has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #207 out of 516 companies for 5-Year Yield-on-Cost %. This puts Recordati SpA in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.26. Recordati SpA's value of 3.30 is 46.3% above this benchmark. Historically, Recordati SpA's own 5-Year Yield-on-Cost % has ranged from 2.17 to 3.94 over the past decade. While the company's 10-year median is 3.01 vs. the industry median of 2.26, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.26, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current 5-Year Yield-on-Cost % of 3.30 is 46.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current 5-Year Yield-on-Cost % is 3.30, which is 10% above median its own 10-year median of 3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.80, compared to a current price of €51.60 — trading 15.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 3.30, which is 10% above median its 10-year median of 3.01 and 46.3% above the Drug Manufacturers industry median of 2.26. Recordati SpA's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current 5-Year Yield-on-Cost % is 3.30 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.60 is trading 15.1% below its estimated GF Value™ of €60.80.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
5-Year Yield-on-Cost %: 3.30 (10% above median its 10-year median of 3.01)
GF Value™: €60.80 vs. price of €51.60 (15.1% below fair value)
Industry Position: 46.3% above the Drug Manufacturers median (#207 of 516)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
96GF Score
Get the complete analysis for MIL:REC
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 